NTRA:NSD-Natera Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 126.73

Change

+1.99 (+1.60)%

Market Cap

USD 14.84B

Volume

0.80M

Analyst Target

USD 56.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+3.25 (+0.73%)

USD 37.69B
ICLR ICON PLC

-4.51 (-1.94%)

USD 23.48B
ILMN Illumina Inc

+1.66 (+1.14%)

USD 22.77B
EXAS EXACT Sciences Corporation

+0.82 (+1.18%)

USD 12.84B
MEDP Medpace Holdings Inc

-11.41 (-3.46%)

USD 10.15B
RDNT RadNet Inc

-0.94 (-1.39%)

USD 4.95B
SHC Sotera Health Co

-0.09 (-0.57%)

USD 4.39B
NEOG Neogen Corporation

+0.23 (+1.60%)

USD 2.98B
GH Guardant Health Inc

+1.28 (+5.87%)

USD 2.52B
VCYT Veracyte Inc

+0.62 (+1.80%)

USD 2.50B

ETFs Containing NTRA

GNOG:LSE Global X Genomics & Biote.. 4.93 % 0.00 %

+0.02 (+1.60%)

USD 5.77M
GNOM Global X Genomics & Biote.. 4.92 % 0.00 %

-0.02 (1.60%)

USD 0.08B
GN0M:XETRA Global X Genomics & Biote.. 4.92 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.92 % 0.00 %

N/A

USD 5.93M
CURE:XETRA VanEck Genomics and Healt.. 4.55 % 0.00 %

-0.06 (1.60%)

N/A
CURG:LSE VanEck Genomics and Healt.. 4.30 % 0.00 %

+0.06 (+1.60%)

USD 5.12M
EKG First Trust Nasdaq Lux Di.. 4.04 % 0.00 %

+0.04 (+1.60%)

USD 2.49M
ARCG:LSE ARK Genomic Revolution UC.. 3.95 % 0.00 %

+5.45 (+1.60%)

USD 3.68M
ARKG:LSE ARK Genomic Revolution UC.. 3.95 % 0.00 %

+0.07 (+1.60%)

USD 3.68M
ATFV Alger 35 ETF 3.94 % 0.00 %

-0.20 (1.60%)

USD 0.02B
FRTY Alger Mid Cap 40 ETF 3.61 % 0.00 %

+0.03 (+1.60%)

USD 0.06B
WRNA:XETRA WisdomTree BioRevolution .. 2.87 % 0.00 %

-0.03 (1.60%)

USD 2.77M
WBIO:LSE WisdomTree BioRevolution .. 2.81 % 0.00 %

+10.20 (+1.60%)

USD 3.58M
WDNA 2.71 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.52 % 0.00 %

+0.15 (+1.60%)

USD 0.04B
FHH:CA First Trust AlphaDEX US H.. 2.43 % 0.77 %

+0.30 (+1.60%)

CAD 0.01B
FHH-F:CA First Trust AlphaDEX U.S... 2.43 % 0.00 %

N/A

CAD 0.01B
WDNA:LSE WisdomTree BioRevolution .. 2.31 % 0.00 %

+0.13 (+1.60%)

N/A
HTEC Robo Global® Healthcare .. 1.92 % 0.00 %

+0.12 (+1.60%)

USD 0.05B
XMLH:XETRA L&G Healthcare Breakthrou.. 1.87 % 0.00 %

+0.06 (+1.60%)

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.87 % 0.00 %

N/A

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.87 % 0.00 %

+0.06 (+1.60%)

USD 0.06B
DOCG:LSE L&G Healthcare Breakthrou.. 1.84 % 0.00 %

+7.25 (+1.60%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.84 % 0.00 %

+0.10 (+1.60%)

USD 0.07B
ZUH:CA BMO Equal Weight US Healt.. 1.67 % 0.39 %

+0.10 (+1.60%)

CAD 0.26B
ZHU:CA BMO Equal Weight US Healt.. 1.67 % 0.00 %

+0.05 (+1.60%)

CAD 0.01B
IS0R:XETRA iShares $ High Yield Corp.. 0.34 % 0.00 %

-0.38 (1.60%)

USD 2.71B
VISM:AU Vanguard MSCI Internation.. 0.19 % 0.00 %

-0.01 (1.60%)

USD 0.29B
ZPRS:F SSgA SPDR ETFs Europe II .. 0.18 % 0.00 %

-0.12 (1.60%)

USD 0.83B
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.18 % 0.00 %

-0.08 (1.60%)

USD 0.83B
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

-0.63 (1.60%)

USD 0.15B
BTEC 0.00 % 0.42 %

N/A

N/A
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

+0.03 (+1.60%)

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

+0.04 (+1.60%)

N/A
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

-0.43 (1.60%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 102.31% 72% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 102.31% 72% C 81% B-
Trailing 12 Months  
Capital Gain 219.30% 72% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 219.30% 72% C 84% B
Trailing 5 Years  
Capital Gain 225.45% 87% B+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 225.45% 87% B+ 85% B
Average Annual (5 Year Horizon)  
Capital Gain 49.63% 82% B 88% B+
Dividend Return 49.63% 82% B 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 91.46% 38% F 22% F
Risk Adjusted Return 54.27% 92% A 81% B-
Market Capitalization 14.84B 93% A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector